A Study to Assess the Safety and Pharmacokinetics of HBI-002, an Oral Carbon Monoxide Therapeutic, in Healthy Volunteers
Condition: Anemia, Sickle Cell Intervention: Drug: HBI-002 Sponsors: Hillhurst Biopharmaceuticals, Inc.; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials